Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 31-40 of 41 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescentsSkinner, S.R.; Davies, C.; Cooper, S.; Stoney, T.; Marshall, H.; Jones, J.; Collins, J.; Hutton, H.; Parrella, A.; Zimet, G.; Regan, D.G.; Whyte, P.; Brotherton, J.M.L.; Richmond, P.; McCaffrey, K.; Garland, S.M.; Leask, J.; Kang, M.; Braunack-Mayer, A.; Kaldor, J.; et al.
2012Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010Murray, C.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.; Abdalla, S.; Aboyans, V.; Abraham, J.; Ackerman, I.; Aggarwal, R.; Ahn, S.; Ali, M.; Alvarado, M.; Anderson, H.; Anderson, L.; Andrews, K.; et al.
2012Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010Vos, T.; Flaxman, A.; Naghavi, M.; Lozano, R.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.; Abdalla, S.; Aboyans, V.; Abraham, J.; Ackerman, I.; Aggarwal, R.; Ahn, S.; Ali, M.; Alvarado, M.; Anderson, H.; Anderson, L.; Andrews, K.; Atkinson, C.; et al.
2017Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)McElvaney, N.; Burdon, J.; Holmes, M.; Glanville, A.; Wark, P.; Thompson, P.; Hernandez, P.; Chlumsky, J.; Teschler, H.; Ficker, J.; Seersholm, N.; Altraja, A.; Mäkitaro, R.; Chorostowska-Wynimko, J.; Sanak, M.; Stoicescu, P.; Piitulainen, E.; Vit, O.; Wencker, M.; Tortorici, M.; et al.
2018Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseBranford, S.; Wang, P.; Yeung, D.T.; Thomson, D.; Purins, A.; Wadham, C.; Shahrin, N.H.; Marum, J.E.; Nataren, N.; Parker, W.T.; Geoghegan, J.; Feng, J.; Shanmuganathan, N.; Mueller, M.C.; Dietz, C.; Stangl, D.; Donaldson, Z.; Altamura, H.; Georgievski, J.; Braley, J.; et al.
2018Pathogenic variants in E3 ubiquitin ligase RLIM/RNF12 lead to a syndromic X-linked intellectual disability and behavior disorderFrints, S.G.M.; Ozanturk, A.; Rodríguez Criado, G.; Grasshoff, U.; de Hoon, B.; Field, M.; Manouvrier-Hanu, S.; E Hickey, S.; Kammoun, M.; Gripp, K.W.; Bauer, C.; Schroeder, C.; Toutain, A.; Mihalic Mosher, T.; Kelly, B.J.; White, P.; Dufke, A.; Rentmeester, E.; Moon, S.; Koboldt, D.C.; et al.
2018A genotype-first approach identifies an intellectual disability-overweight syndrome caused by PHIP haploinsufficiencyJansen, S.; Hoischen, A.; Coe, B.; Carvill, G.; van Esch, H.; Bosch, D.; Andersen, U.; Baker, C.; Bauters, M.; Bernier, R.; van Bon, B.; Claahsen-van der Grinten, H.; Gecz, J.; Gilissen, C.; Grillo, L.; Hackett, A.; Kleefstra, T.; Koolen, D.; Kvarnung, M.; Larsen, M.; et al.
2016Characterization of leukemias with ETV6-ABL1 fusionZaliova, M.; Moorman, A.V.; Cazzaniga, G.; Stanulla, M.; Harvey, R.C.; Roberts, K.G.; Heatley, S.L.; Loh, M.L.; Konopleva, M.; Chen, I.M.; Zimmermannova, O.; Schwab, C.; Smith, O.; Mozziconacci, M.J.; Chabannon, C.; Kim, M.; Frederik Falkenburg, J.H.; Norton, A.; Marshall, K.; Haas, O.A.; et al.; Annual Meeting of the American-Society-of-Hematology (5 Dec 2015 - 8 Dec 2015 : Orlando, FL)
2012Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010Salomon, J.A.; Vos, T.; Hogan, D.R.; Gagnon, M.; Naghavi, M.; Mokdad, A.; Begum, N.; Shah, R.; Karyana, M.; Kosen, S.; Farje, M.R.; Moncada, G.; Dutta, A.; Sazawal, S.; Dyer, A.; Seiler, J.; Aboyans, V.; Baker, L.; Baxter, A.; Benjamin, E.J.; et al.
2017Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosisHerold, T.; Schneider, S.; Metzeler, K.; Neumann, M.; Hartmann, L.; Roberts, K.; Konstandin, N.; Greif, P.; Braeundl, K.; Ksienzyk, B.; Huk, N.; Schneider, I.; Zellmeier, E.; Jurinovic, V.; Mansmann, U.; Hiddemann, W.; Mullighan, C.; Bohlander, S.; Spiekermann, K.; Hoelzer, D.; et al.